Longevity research community VitaDAO announced it raised a $4.1M round, including participation from Pfizer's venture arm and Balaji Srinivasan, former CTO of Coinbase.  The investments were voted on by community members. VitaDAO was created by early-stage drug development and research protocol Molecule, which raised $12.7M in June 2022. Molecule also launched AthenaDAO for women's health research and ValleyDAO for synthetic biology.  VitaDAO expects the traditional sources of funding from the round to build credibility between the community and pharmaceutical companies.  "Translating academic science into the biotech space is often referred to as the valley of death, as many projects fail to find sufficient funding to advance. Decentralized Science caught our attention as an emerging area to address the valley of death challenge," said Pfizer Ventures' executive director Michael Baran.